K2B-WEEKLY REPORTS
Bi-weekly report
#9(270) 11(366) #12(252) #13(209)
Fig1.1 EL images of SEII0042
#9 #11 #12 #13
Fig1.2 IR images of SEII0042
100
90
group A #3 (335) group B #15(409)
Fig2.1 EL images of SEII0043
型工艺制作电池片，A组在磷扩散的程序中加了700℃吸杂1h的过程，B组则是普通的高低温扩散程序。
由于在烧结温度没有调节好，所以吸杂组的FF普遍较差，从而导致EFF也较低，但即使是在没有烧结好的情况下，吸杂组的电流仍比未吸杂组的电流高，由此可以看出，吸杂对电池片性能有比较正面的影响，但结果还有待更多试验的进一步证实。
同时，本批电池片在实验室制绒，从Fig2.3可以看出，实验室制绒的效果不如车间，尤其是在长波部分有较大的差距。
Fig2.2的QE测试结果显示，反射率在短波部分的损失较大，对QE响应有一定的影响。
基于美国食品药品监督管理局不良事件报告系统数据库的他克莫司致药品不良反应信号挖掘与分析
!C"#!!%&’()’*+,-’-.’-’(/0+0,1.2)34)05+-6,07+*’(0,186+-’"#"#9,(:"#;,:$中国医院用药评价与分析!"#"#年第"#卷第$期基于美国食品药品监督管理局不良事件报告系统数据库的他克莫司致药品不良反应信号挖掘与分析’程!艺<!"!="!陈!晨E !余春飞=!陈!乾$!陈!力<!"p"<:四川大学华西第二医院药学部I 循证药学中心!四川成都!C<##E<$":出生缺陷与相关妇儿疾病教育部重点实验室!四川成都!C<##E<$=:重庆医科大学附属儿童医院药学部I 儿童发育疾病研究教育部重点实验室!重庆!E###<E $E:四川大学华西药学院!四川成都C<##E<$$:宜宾市第一人民医院药学部!四川宜宾!CEE####中图分类号!>?@?A $文献标志码!B 文章编号!<C@"D"<"E ""#"###$D #C"#D #$F G H !<#A <E##?I J :+00-:<C@"4"<"EA "#"#A #$A #"?摘!要!目的)利用美国食品药品监督管理局!1,,.’-..2)3’.K +-+0*2’*+,-"U F B #不良事件报告系统!U F B’.&52055&5-*257,2*+-30/0*5K"U B %>S #"挖掘与分析免疫抑制剂他克莫司致药品不良反应信号"为临床安全用药提供参考&方法)采用回顾性研究方法"利用报告比值比!257,2*+-3,..02’*+,">G >#法和比例报告比值!72,7,2*+,-’(257,2*+-32’*+,"R >>#法"对U %B >S 数据库中"##?年第<季度至"#<?年第<季度共E<个季度的他克莫司致不良事件报告进行数据挖掘与分析&结果)使用>G >法得到他克莫司致药品不良反应信号共<=C$个"将其信号强度按照降序排列得到排序居前$#位的信号"其中原研药说明书中未提及的不良反应共<E 个"按世界卫生组织术语集分类累及"个新的系统(新的不良反应主要集中在泌尿系统损害’全身性损害’免疫功能紊乱’呼吸系统损害’代谢和营养障碍以及中枢和外周神经系统损害&结论)他克莫司药品说明书未收录的不良反应较多且累及器官和!或#系统分布广泛"建议临床用药时需谨慎&关键词!他克莫司(不良反应信号(比例失衡法’基金项目.四川省科技厅项目#;,:"#<?T F >#<C=$"药师+研究方向.抗肿瘤药物+%4K ’+(.<$E#"Q="=Cqcc:N ,K p 通信作者.副主任药师+研究方向.临床药学(医院合理用药+%4K ’+(.<=C@EQ$"qcc:N ,K 8("("7’">9"’;/3(3)*9>O$%3$6%47@$’.#()"?(7"’;32’43$>Q /5’.%);(-43:’3$>)"#,$b f ?fP ))>’">6%479>-("(3#%’#()"9>O$%3$0O$"#@$&)%#("7?/3#$-6’#’Q ’3$!8V %;bf +<&"&=&8V %;865-E &f g86)-15+=&8V %;l +’-$&8V %;^+<&"#<:F 57*:,1R 6’2K ’N /&h50*86+-’S5N ,-.V ,07+*’(,1S+N 6)’-g -+&520+*/&S+N 6)’-865-3.)C<##E<&86+-’’":[5/^’L,2’*,2/,1M +2*6F 515N *0’-.>5(’*5.F +05’050,1h,K 5-’-.86+(.25-&P +-+0*2/,1%.)N ’*+,-&S+N 6)’-865-3.)C<##E<&86+-’’=:F 57*:,1R 6’2K ’N /&86+(.25-j 0V ,07+*’(,186,-3c+-3P 5.+N ’(g -+&520+*/I P +-+0*2/,1%.)N ’*+,-[5/^’L,2’*,2/,186+(.F 5&5(,7K 5-*’-.F +0,2.520&86,-3c+-3E###<E &86+-’’E:h50*86+-’SN 6,,(,1R 6’2K ’N /&S+N 6)’-g -+&520+*/&S+N 6)’-865-3.)C<##E<&86+-’’$:F 57*:,1R 6’2K ’N /&*65U +20*R 5,7(5j 0V ,07+*’(,1f +L+-&S+N 6)’-f +L+-&CEE###&86+-’$9:?5@925!G M T %8O H 9%.O ,K +-5’-.’-’(/X 5*65’.&5205.2)325’N *+,-0+3-’(0N ’)05.L/*65+K K )-,0)772500+&5’35-**’N 2,(+K )0’N N ,2.+-3*,*65g :S:U ,,.’-.F 2)3B .K +-+0*2’*+,-#U F B $B .&5205%&5-*>57,2*+-3S/0*5K #U B %>S $.’*’L’05&0,’0*,72,&+.5251525-N 501,2*65’77(+N ’*+,-0’15*/,1.2)3)05+-N (+-+N :P %O V G F S .O 65K 5*6,.,125*2,075N *+&5’-’(/0+0K 5*6,.&257,2*+-3,..02’*+,#>G >$K 5*6,.’-.72,7,2*+,-’(257,2*2’*+,#R >>$K 5*6,.&.’*’K +-+-3’-.’-’(/0+0Z 525N ,-.)N *5.,-*’N 2,(+K )04+-.)N 5.’.&52055&5-*257,2*0,1E<c)’2*52012,K*65<0*c)’2*52,1"##?*,*65<0*c)’2*52,1"#<?+-*65U %B >S .’*’L’05:>%Sg ^O S .B *,*’(,1<=C$’.&5205.2)325’N *+,-0+3-’(0N ’)05.L/*’N 2,(+K )0Z 525,L*’+-5.L/)0+-3>G >K 5*6,.:O 650+3-’(0*25-3*6Z ’02’-Y5.+-.50N 5-.+-3,2.52*,,L*’+-*65*,7$#0+3-’(0&’K ,-3Z 6+N 6*6525Z 525<E ’.&5205.2)325’N *+,-0-,*K 5-*+,-5.+-*65,2+3+-’(.2)3075N +1+N ’*+,-&’-."-5Z0/0*5K 0Z 525+-&,(&5.’N N ,2.+-3*,*65h ,2(.V 5’(*6G 23’-+X ’*+,-O 52K +-,(,3/S5*:;5Z’.&5205.2)325’N *+,-0K ’+-(/1,N )05.,-)2+-’2/0/0*5K.’K ’35&0/0*5K +N.’K ’35&+K K )-5./01)-N *+,-&2507+2’*,2/0/0*5K.’K’35&K5*’L,(+N’-.-)*2+*+,-’(.+0,2.520&’-.N5-*2’(’-.752+7652’(-52&,)00/0*5K.’K’35: 8G;8^g SH G;S.O6525’25K’-/’.&5205.2)325’N*+,-0Z+*6Z+.52’-35,1,23’-0’-.I,20/0*5K0+-&,(&5.*6’*’25-,* +-N().5.+-*65+-0*2)N*+,-0,1*’N2,(+K)0:H*+025N,K K5-.5.*,L5N’)*+,)0+-N(+-+N’(’.K+-+0*2’*+,-:A0B CD@6?!O’N2,(+K)0’B.&5205.2)325’N*+,-0+3-’(0’>’*+,+K L’(’-N5K5*6,.!!免疫抑制剂的种类较多且发展非常迅速&从最早的硫唑嘌呤到环孢素B&再到他克莫司&他克莫司现已成为器官移植的首选药物)<*+他克莫司是一种从土壤真菌筑波链霉菌中提取的中性疏水性大环内酯类新型免疫抑制剂)"*+该药可能通过与细胞质内蛋白质结合&形成复合物&竞争性抑制钙调素&以阻止其发挥作用&后者介导O细胞内的钙依赖性抑制信号传递系统&从而阻止一系列淋巴因子基因转录&发挥免疫抑制作用)=4$*+他克莫司有效血药浓度范围窄&而患者药动学个体差异大&其血药浓度受年龄(肝肾功能和药物基因组学等因素影响)C4@*+他克莫司上市以来关于其不良反应报告文献局限&对该类药物不良反应的研究还不够完善+因此&充分探索该药的不良反应十分必要+现利用上市后真实世界的数据以及数据挖掘的方法&对他克莫司致药品不良反应进行研究&即进行不良反应信号检测&充分挖掘他克莫司的不良反应&为临床合理用药提供参考+EF资料与方法EG EF资料来源研究数据为美国食品药品监督管理局#1,,.’-..2)3’.K+-+0*2’*+,-&U F B$不良事件报告系统#U F B’.&52055&5-* 257,2*+-30/0*5K&U B%>S$)Q*中自"##?年第<季度至"#<?年第<季度共E<个季度的关于他克莫司的不良反应报告+以U F B批准药品及不良反应公众数据库#7)L(+N.’06L,’2.$中药品名称为标准&以他克莫司的通用名"O’N2,(+K)0%做为关键检索词&在U B%>S数据库中进行检索+共收集到?C=#?例报告&删除其中信息不完全和与药物治疗无关的报告&筛选出其中用药名称为"O’N2,(+K)0%且为首要怀疑药物的报告&最终纳入$?#?=例+EG<F信号生成条件与挖掘方法本研究主要采用的信号检测方法为报告比值比#257,2*+-3 ,..02’*+,&>G>$法和比例报告比值#72,7,2*+,-’(257,2*+-3 2’*+,&R>>$法&主要计算目标药品不良反应与数据库中对应的药品不良反应等发生之间的关系&若两者之间的关系达到失衡&则提示信号生成&该方法具有较高的可信度和灵敏性+本方法以比例失衡法)Q*四格表#见表<$为基础&再用>G>法和R>>法的公式#见表"$计算>G>和R>>+表EF比例失衡法所用四格表5’QEFP)4%*);>#’Q;$)*%’#()(-Q’;’".$-$#,)>药品种类目标不良反应报告数其他不良反应报告数合计目标药物’L’d L其他药物N.N d.合计’d N L d.-e’d L d N d.EG HF数据处理使用P+N2,0,1*%W N5("#<#软件进行统计&并对标准化后的表<F@D@法与+@@法的公式及阈值5’Q<FP)%-4;’3’">#,%$3,);>O’;4$3)*@D@’">+@@方法公式阈值>G>6;6<#52=$#>2?$<5?>=9&#(-6;6$<<5@<>@<=@<?()槡$\#*<5(-#>G>$A<B?C<5@<>@<=@<?()槡’‘=’>G>的?$\#*下限‘<&则提示生成<个信号R>>.66<52#5@>$=2#=@?$9&#(-.66$<<5C<5@>@<=C<=@?()槡$\#*<D(-#.66$A<A?C<5C<5@>@<=C<=@?()槡’‘=’R>>的?$\#*下限‘<&则提示生成<个信号结果进行统计和计算+<A=A<!标准化.采用世界卫生组织#Z,2(.65’(*6,23’-+X’*+,-& hV G$药品不良反应术语集&对每例报告的不良反应名称按照系统和器官进行规范化编码&可以有效减少因药品不良反应报告术语的差异所导致的差异性&提高研究的准确度和可信度)?4<#*+采用首选术语#72515225.*52K&R O$+<A=A"!统计与计算.将上述标准化后的术语进行统计&筛选出报告数‘=例的数据&按比例失衡法四宫格#见表<$及>G>法(R>>法的计算公式#见表"$&计算表中各值+<A=A=!筛选.为了避免出现假阳性信号&要求数据同时满足>G>‘=和R>>‘=且?$\#*‘<&将不符合条件的数据进行筛除&将符合条件的数据进行排序&以便进行下一步的数据分析+<F结果<G EF药品不良反应信号数结果对检索到的用药名称为"O’N2,(+K)0%#他克莫司$的?C =#?例报告进行筛选后&得到$?#?=例报告+对筛选出的报告进行统计后&共获得<@@个信号+他克莫司致药品不良反应信号强度和报告数居前$#位的信号见表=+<G<F新的药品不良反应信号将上述二次筛选后的信号与其在h V G药品不良反应术语集累及的系统(器官相对应&结果见表E+HF讨论本研究所得的不良反应信号与他克莫司药品说明书和文献研究)<<4<=*基本一致&主要不良反应表现为肝肾毒性(神经毒性(糖代谢紊乱(心血管并发症(脓肿和感染等+脓肿(感染是接受联合免疫抑制疗法的移植受者常会发生的不良反应&可发生细菌(病毒和真菌等感染+他克莫司肾毒性表现为血浆肌酐急性升高或偶尔进展的慢性肾病&前者可以在降低剂量中国医院用药评价与分析!"#"#年第"#卷第$期!%&’()’*+,-’-.’-’(/0+0,1.2)34)05+-6,07+*’(0,186+-’"#"#9,(:"#;,:$!C"<!!表HF他克莫司致药品不良反应信号强度和报告数居前J=位的信号后大幅度逆转&而后者通常不可逆+心血管并发症主要表现为高血压&其机制可能是通过刺激肾钠氯协同转运蛋白来介导该反应+由肾血管收缩和钠潴留引起的高血压通常在治疗开始后的前几周内发生&减少剂量通常对缓解血压升高有效&但也有可能需要抗高血压药)<E*+他克莫司的神经毒性主要表现为震颤(可复性后部脑病综合征和癫痫发作等&其损害较严重&临床药师(医师应重点监护该类不良反应的发生+HG EF新的不良反应他克莫司所致新的不良反应共涉及Q个系统&分别为泌尿系统损害(全身性损害(免疫功能紊乱(呼吸系统损害(白细胞和网状内皮系统异常(肝胆系统损害(肌肉骨骼肌系统损害和胶原组织损害+但大部分与药品说明书中记载的不良反应尚有联系+完全与药品说明书中记载的不良反应无关的信号有骨坏死和纤维性肺泡炎+上述新的不良反应信号需要重点关注+ HG<F研究的局限性本研究的优点是利用美国U B%>S数据库为自发呈报系统&覆盖人群广&数据库容量大)<$*+但是&本研究所使用数据仅包含发生不良反应患者的基本信息&存在一定缺陷.#<$患者的诊断不能提供&无法分析药品不良反应与原发疾病的关系’#"$不良反应发生时间特点不能提供&移植患者需长期服!C""!!%&’()’*+,-’-.’-’(/0+0,1.2)34)05+-6,07+*’(0,186+-’"#"#9,(:"#;,:$中国医院用药评价与分析!"#"#年第"#卷第$期表IF他克莫司致药品不良反应信号与累及器官和"或#系统5’QIF9>O$%3$>%47%$’.#()"3(7"’;3.’43$>Q/#’.%);(-43’">)%7’"3’">X)%3/3#$-3("O);O$>累及器官(系统有信号的R O不良反应种类I种报告数I例泌尿系统损害肾功能异常(急性肾衰竭(肾病(菌尿(肾小管坏死(肾间质纤维化"(蛋白尿和慢性肾衰竭"Q E@==全身性损害死亡(发热(感染性休克"(纤维性肺泡炎"(腹水和多脏器功能衰竭"C=C#$免疫功能紊乱肺炎(脓毒病"(菌尿(感染"(细菌感染(支气管炎(真菌感染和咽炎Q"?"$呼吸系统损害肺炎(心4肺呼吸衰竭"(胸腔积液(支气管炎(纤维性肺泡炎"(上呼吸道感染和咽炎@"<<E 交感副交感神经系统损害高血压<@C$心血管系统一般损害高血压(心力衰竭"?"@心外血管损害血栓形成<@##血小板&出血和凝血障碍血栓形成<@##中枢及外周神经系统损害震颤(可复性后部脑病综合征(癫痫发作(神经损害和脑病$<E@?代谢和营养障碍糖尿病(高血糖(高钾血症(乳酸性酸中毒和高脂血症$<"<<红细胞异常贫血(缺铁性贫血"$??白细胞和网状内皮系统异常非典型性淋巴细胞异常"(全血细胞减少"$#E 血小板(出血和凝血障碍血小板减少(全血细胞减少"EQ$女性生殖系统损害早产<"E=新生儿和婴儿异常早产<"E=红细胞异常全血细胞减少<""@肌肉骨骼系统损害骨坏死"<<?#胶原组织损害纤维性肺泡炎"<<Q<肝胆系统损害肝衰竭"(肝功能异常和淋巴结"=E$"神经紊乱情绪不稳定<<E# !!注.""%代表未在他克莫司药品说明书中出现的新的R O;,*5.""%2572505-*0-5ZR O*6’*.,50-,*+-N().5+-.2)3+-0*2)N*+,-0,1*’N2,(+K)0用免疫抑制剂&如能明确不良反应的发生主要集中在术后什么阶段&则患者和临床可重点监护此阶段’#=$该数据库不能提供使用他克莫司但未发生不良反应的患者数量&从而无法计算该药整体不良反应发生率)<C*’#E$报告不够完整(规范导致不同不良反应同种表达或同种不良反应不同表达等&最终与hV G药品不良反应术语集累及的系统(器官相对应时存在差异)<@4<Q*’#$$该数据库是针对美国人群&可能与中国人群存在种族差异+本研究所用方法为比例失衡法&该方法简便易行且较为敏感&但容易出现假阳性)<?*+同时使用R>>法和>G>法进行计算并提高阈值&筛选出R>>法和>G>法重叠的信号&可以避免假阳性+通过比较他克莫司不良反应信号强度排序和发生频率排序&可以发现他克莫司的不良反应发生次数和经挖掘后得到的信号强度在关联性方面存在着一定程度的差异&如肾功能异常(急性肾衰竭和肺炎等发生频率较高&但信号强度较低&这可能与>G>法和R>>法挖掘药品不良反应的局限性有关+总之&他克莫司口服给药后吸收不规则&生物利用度差异显著&治疗窗窄+临床用药时&应尽量避免使用对他克莫司代谢干扰大的药物+除药物基因组学因素外&年龄(肝功能和白蛋白水平等对他克莫司血药浓度均有影响+因此&条件允许的情况下&应常规进行血药浓度监测&再根据需要浓度调整剂量&确保安全有效)"#*+他克莫司所致不良反应与药品说明书(文献基本一致&其中也发现了维性肺泡炎(骨坏死等新的不良反应&获得了相对真实完整的药品安全信息&可为临床用药提供参考&从而促进临床合理用药+参考文献)<*陆燕红&杨珏&曹丹丹:他克莫司临床应用的新进展)T*:北方药学&"#<?&<C#$$.<$@4<$Q:)"*丁春雷&刘丽宏&马萍&等:他克莫司治疗药物监测研究进展)T*:中国药房&"##Q&<?#"#$.<$Q#4<$Q=:)=*[+-,O&V’*’-’Y’V&P+/’*’S&5*’(:U[4$#C&’-,&5(+K K)-,40)772500’-*+0,(’*5.12,K’S*257*,K/N50:":H K K)-,0)772500+&55115N*,1U[4$#C+-&+*2,)T*:T B-*+L+,*.O,Y/,&<?Q@&E##?$.<"$C4<"C$:)E*T P235-05-[B&[,51,5.4;+5(05-R M&[’2’K752+0;:8’(N+-5)2+-76,076’*’05’N*+&+*/’-.+K K)-,0)772500+,-:B25&+5Z,-*652,(5,1N’(N+-5)2+-76,076’*’05’N*+&+*/’-.*65+K K)-,0)772500+&55115N*,1N/N(,07,2+-B’-.*’N2,(+K)0)T*:SN’-.T H K K)-,(&"##=&$@#"$.=4?Q:)$*T’K50F b:B-5Z+K K)-,0)772500’-*.*’N2,(+K)0)T*:R,0*32’.P5.T&<??C&@"#Q$"$.$QC:)C*付绍杰&王彦斌&于立新&等:肾移植受者他克莫司剂量I浓度个体差异影响因素及其变化规律)T*:南方医科大学学报&"##Q&"Q#<"$."<C<4"<CE:)@*周永恒&石磊&唐镜波:影响他克莫司血药浓度的因素)T*:中国药房&"##$&<C#"E$.<?#?4<?<<:)Q*g:S:U,,.’-.F2)3B.K+-+0*2’*+,-:U F BB.&5205%&5-*>57,2*+-3 S/0*5K#U B%>S$l)’2*52(/F’*’%W*2’N*U+(50)%M I G^*:#"#<?4#Q4#<$)"#"#4#<4<$*:6**70.I I1+0:1.’:3,&I5W*5-0+,-0I U R F4l F%4U B%>S I U R F4l F%4U B%>S:6*K(:)?*任经天&王胜锋&侯永芳&等:常用药品不良反应信号检测方法比较研究)T*:中国药物警戒&"#<<&Q#C$.=$C4=$?:)<#*!李婵娟:药品不良反应信号检测方法理论及应用研究)F*:西安.第四军医大学&"##Q:)<<*!李旸&吴斌&徐珽&等:器官移植术后应用他克莫司致不良反应文献分析)T*:华西医学&"##Q&"=#C$.<"?Q4<"??:)<"*!孙雨平&史国兵&樊蓉&等:他克莫司致不良反应C@例文献分析)T*:医药导报&"#<E&==#<<$.<$=$4<$=@:中国医院用药评价与分析!"#"#年第"#卷第$期!%&’()’*+,-’-.’-’(/0+0,1.2)34)05+-6,07+*’(0,186+-’"#"#9,(:"#;,:$!C"=!!)<=*!史天陆&孙言才&沈爱宗&等:他克莫司临床不良反应与防治)T*:中国医院用药评价与分析&"##?&?#<$.C@4C?:)<E*!V,,2-%T&h’(06SM&P N8,2K+N Y T B&5*’(:O65N’(N+-5)2+-+-6+L+*,2 *’N2,(+K)0’N*+&’*50*6525-’(0,.+)KN6(,2+.5N,*2’-07,2*52*,N’)056/752*5-0+,-)T*:;’*P5.&"#<<&<@#<#$.<=#E4<=#?:)<$*!周健&陈力:索拉非尼的不良反应信号挖掘)T*:中国医药导报& "#<Q&<$#<E$.<<<4<<$:)<C*!S’Y’5.’O&O’K,-B&[’.,/’K’[&5*’(:F’*’K+-+-3,1*657)L(+N &520+,-,1*65U F BB.&5205%&5-*>57,2*+-3S/0*5K)T*:H-*T P5.SN+&"#<=&<##@$.@?C4Q#=:)<@*!T+V V&O’-3_h&F,-3k&5*’(:B.&5205%&5-*R2,1+(50,1B-*+4 8O^B4E’-.B-*+4R F4<P,-,N(,-’(B-*+L,.+50B(,-5,2+-8,K4L+-’*+,-.B-’(/0+0,1S7,-*’-5,)0>57,2*0S)LK+**5.*,U B%>S)T*:8(+-F2)3H-&50*+3&"#<?&=?#=$.=<?4==#:)<Q*!B(’*’Z+f P&V’-05->B:%K7+2+N’(50*+K’*+,-,1)-.524257,2*+-3+-*65g:S:U,,.’-.F2)3B.K+-+0*2’*+,-B.&5205%&5-*>57,2*+-3S/0*5K#U B%>S$)T*:%W752*G7+-F2)3S’1&"#<@&<C#@$.@C<4@C@:)<?*!李苑雅&张艳&沈爱宗:基于自发呈报系统药品不良反应信号检测方法的研究进展)T*:安徽医药&"#<$&<?#@$.<"==4<"=C:)"#*!陈惠芳&刘锋&吴丽荣&等:环孢素B和他克莫司血药浓度检测方法比较分析)T*:中国处方药&"#<?&<@#?$.E<4E":#收稿日期."#"#4#<4<$$#上接第C<?页$配置了前置审核处方&可以将药名和适应证配对&避免选错药品)<$*+也可以借鉴"#<?年H SP R发布的,易混淆药品目录-)<#*及区分方法&制定符合本院情况的易混淆药品目录及区分方法&如针对易混淆的药品&将不同的字加粗或大写或斜体等&以便区分+R F8B循环和根本原因方法是着眼于改进医疗系统&找出系统及流程缺陷&并采取措施加以改善&而不是惩罚个人)?&<C4<?*+建议对于医院常发生的用药错误等不良事件&可以采用以上"个工具&既可以改善患者用药安全性&又可以保障医务人员执业安全+通过^B SB药品苯巴比妥与苯妥英钠血药浓度电子录入错误的根本原因分析和R F8B循环&可以为类似^B SB药品用药错误的防范提供参考+参考文献)<*中国抗癫痫协会:临床诊疗指南!癫痫病分册)P*:"#<$修订版:北京.人民卫生出版社&"#<$.E":)"*V+5K Y58&M5235K’--;&8(5K5-*V h&5*’(:8,-05-0)0b)+.54(+-50 1,2O652’75)*+N F2)3P,-+*,2+-3+-;5)2,70/N6,76’24K’N,(,3/.g7.’*5"#<@)T*:R6’2K’N,70/N6+’*2/&"#<Q&$<#<4#"$.?4C":)=*^’K L52*M^&SN62,5.52S>&b’(’-*52h^:F,50O’((P’-(5**52+-3 725&5-*.2)3-’K5N,-1)0+,-522,200H-N,K7(5*5’-.N,-1(+N*+-35&+.5-N50)3350*-55.1,2.51+-+*+&50*)./)T*:M P T l)’(S’1&"#<C&"$#E$."<=4"<@:)E*^’K L52*M^&^+-ST&O’-V:F50+3-+-30’15.2)3-’K50)T*:F2)3 S’1&"##$&"Q#C$.E?$4$<":)$*U(/--%B&M’2Y52[;&8’2-’6’-M T:;’*+,-’(,L052&’*+,-’(0*)./,1 7250N2+7*+,-.+075-0+-3’N N)2’N/’-.0’15*/+-$#76’2K’N+50)T*:TB KR6’2KB00,N.h’06&"##=&E=#"$.<?<4"##:)C*8+-’T^&b’-.6+O[&86)2N6+((h&5*’(:V,Z K’-/6,07+*’( 76’2K’N/K5.+N’*+,-.+075-0+-3522,203,)-.5*5N*5.0)T*:T*8,K KT l)’(R’*+5-*S’1&"##C&="#"$.@=4Q#:)@*F5V5-’)8&M5N Y52P h&M5((,;P&5*’(:O’((K’-(5**52+-3’0’0*2’*53/1,2.+11525-*+’*+,-+-(,,Y4’(+Y5&0,)-.4’(+Y5.2)3-’K50.*652,(5,11’K+(+’2+*/+-.+11525-*+’*+-3.2)3.,775(3’-3520)T*:B77(%23,-&"#<C&$".@@4QE:)Q*H-0*+*)*51,20’15K5.+N’*+,-72’N*+N50#H SP R$:O,7K5.+N’*+,-522,20 257,2*5.*,H SP R+-"#<?)%M I G^*:#"#<?4<"4"Q$)"#"#4#=4<E*:6**70.I I Z Z Z:+0K7:,23I5&5-*0I*,74K5.+N’*+,-4522,204257,2*5.4+0K74"#<?:)?*王跃建&曾勇&章成国&等:基于根本原因分析法的不良事件改进)T*:中国卫生质量管理&"#<Q&"$#=$.@4Q:)<#*!H-0*+*)*51,20’15K5.+N’*+,-72’N*+N50#H SP R$:^+0*,1N,-1)05..2)3 -’K50)%M I G^*:#"#<?4#"4"Q$)"#"#4#=4<E*:6**70.I I Z Z Z:+0K7:,23I25N,K K5-.’*+,-0I N,-1)05.4.2)34-’K504(+0*:)<<*!H-0*+*)*51,20’15K5.+N’*+,-72’N*+N50#H SP R$:^,,Y4’(+Y5.2)3 -’K50Z+*625N,K K5-.5.*’((K’-(5**520)%M I G^*:#"#<C4<<4"#$)"#"#4#=4<E*:6**70.I I Z Z Z:+0K7:,23I25N,K K5-.’*+,-0I*’((4K’-4(5**5204(+0*:)<"*!H-0*+*)*51,20’15K5.+N’*+,-72’N*+N50#H SP R$:P5.+N’*+,-0’15*/05(1’00500K5-*&1,2V,07+*’(0)%M I G^*:#"#<<4#E4#<$)"#"#4#=4<E*:6**70.I I Z Z Z:+0K7:,23I’00500K5-*0I6,07+*’(0:)<=*!H-0*+*)*51,2S’15P5.+N’*+,-R2’N*+N50&中国药理学会药源性疾病学专业委员会&北京市卫生和计划生育委员会临床安全用药组&等:"#<<版H SP R医院用药安全自我评估标准#中文版$#续一$)T*:药物不良反应杂志&"#<@&<?#C$.EEQ4E$Q:)<E*!H-0*+*)*51,20’15K5.+N’*+,-72’N*+N50#H SP R$:b)+.5(+-501,20’15 5(5N*2,-+N N,K K)-+N’*+,-,1K5.+N’*+,-+-1,2K’*+,-)%M I G^*:#"#<?4#<4<C$)"#"#4#=4<E*:6**70.I I Z Z Z:+0K7:,23I250,)2N50I3)+.5(+-5040’1545(5N*2,-+N4N,K K)-+N’*+,-4K5.+N’*+,-4+-1,2K’*+,-:)<$*!S5,’-549’X c)5X%&>,.2+3)5X4P,-3)+,>&B(c’6*’-+S&5*’(: %W7(,42+-3*657,*5-*+’(1,2)0+-3.2)3+-.+N’*+,-0*,725&5-*(,,Y4’(+Y5’-.0,)-.4’(+Y5.2)3522,20)T*:%W752*G7+-F2)3S’1&"#<@&<C#<#$.<<#=4<<#?:)<C*!曾勇&王跃建&章成国&等:应用R F8B促进多学科协作诊疗开展)T*:中国卫生质量管理&"#<Q&"$#=$.E4C:)<@*!张赟&施娣&龚斐&等:医疗安全不良事件管理持续改进的实践)T*:中国卫生质量管理&"#<C&"=#C$."E4"$&"Q:)<Q*!伍启康&李炜煊&赵伟成&等:应用R F8B降低检验科危急值漏报率)T*:中国卫生质量管理&"#<Q&"$#=$.<$4<@:)<?*!池末珍&曹登科&刘治东&等:R F8B循环在危急值管理中的应用)T*:中国卫生质量管理&"#<$&""#"$.E"4EE:#收稿日期."#<?4<"4#=$!C"E!!%&’()’*+,-’-.’-’(/0+0,1.2)34)05+-6,07+*’(0,186+-’"#"#9,(:"#;,:$中国医院用药评价与分析!"#"#年第"#卷第$期。
K2 blackpearl产品白皮书
K2 产品白皮书K2 BLACKPEAL8月/2014年1概述本文档是上海斯歌信息技术有限公司对其所有的K2 blackpearl 产品的技术白皮书，本白皮书包含以下内容：一、K2 blackpearl 流程平台总体功能介绍二、K2 blackpearl 流程设计工具介绍三、K2 blackpearl 后台管理功能介绍四、K2 blackpearl 统计分析工具介绍五、K2 blackpearl 表单设计工具介绍六、 K2 blackpearl 移动办公APP2K2 blackpearl 流程平台总体功能介绍2.1产品概述K2 blackpearl 是美国 SourceCode®公司基于微软.NET 技术平台研发的 BPM 产品，2007 年发布该产品，是全球第一家基于微软W WF 技术构建的遵循W FMC 标准的.NET 平台B PM 产品。
K2 blackpearl 基于微软多个技术标准研发，其中包括：WWF、WCF、WPF。
与微软全线服务端产品紧密集成，包括：Exchange Server 2010/2013、SharePoint Server 2010/2013、Communication Server、BizTalk Server 等，采用 k2blackpearl 作为企业流程平台能有效保护客户在微软平台的投资。
K2 blackpearl 基于微软W indow Server 2008/2012 平台运行，产品运行数据库平台基于M icrosoft SQL Server 2008/2012，流程业务数据库可以选择 SQL Server、Oracle、DB2、Informix 等大型数据库系统之一。
2.2功能概述2.2.1常规流程功能K2 blackpearl 支持的常规流程功能包括：动态路由、串行流程、并行流程、串并混合流程、任务超时处理、流程跟踪及回溯、任务自动提醒、子流程呼叫、流程动态维护。
缓解2型糖尿病中国专家共识
·4037··指南·共识·【编者按】 2型糖尿病（T 2DM ）是一种终身性代谢性疾病，目前没有被治愈的证据，但经研究证实，针对超重和肥胖的T 2DM 患者采取强化生活方式干预、药物治疗（包括强化胰岛素治疗和口服降糖药治疗）以及代谢手术治疗可以实现T 2DM 缓解。
什么是T 2DM 缓解？近期美国糖尿病协会（ADA ）发布的《2021 共识报告：缓解2型糖尿病的定义和解释》，将停用降糖药物至少3个月后，糖化血红蛋白<6.5%作为T 2DM 缓解的诊断标准；当糖化血红蛋白不能反映真实血糖水平，可以用空腹血糖<7.0 mmol/L 或通过动态葡萄糖监测计算估计的糖化血红蛋白<6.5%作为诊断T 2DM 缓解的替代标准。
目前我国T 2DM 呈高发趋势，患者承受着心理、身体、社会、经济等多方面的压力，若能实现糖尿病缓解，对于患者及其家庭，乃至整个社会的意义重大。
因此，由邹大进教授、张征教授、纪立农教授牵头组织国内专家，结合国内外研究证据及ADA 的共识报告，制定了一部符合我国糖尿病患者健康需求的《缓解2型糖尿病中国专家共识》，以期指导临床医生规范开展T 2DM 缓解诊疗工作，帮助T 2DM 患者获得安全、有效且经济的干预措施。
缓解2型糖尿病中国专家共识《缓解2型糖尿病中国专家共识》编写专家委员会【摘要】 2型糖尿病（T2DM）是一种以高血糖为特征的进展性疾病，一直被认为需要长期使用降糖药物治疗。
近年来大量研究结果显示，通过生活方式干预、药物治疗以及代谢手术能够促进合并超重和肥胖的T2DM 缓解，使患者在较长时间内免于使用降糖药物。
T2DM 缓解有助于减轻患者心理负担、增强患者依从健康生活方式的信心，提升患者生活质量，远期还可以延缓疾病进展速度，降低终生并发症的发生风险。
为帮助我国临床医生规范开展在超重和肥胖T2DM 患者中缓解T2DM 相关的临床诊疗工作，促进相关研究的发展，使患者获得安全、有效的干预措施，特制定《缓解2型糖尿病中国专家共识》。
多种维生素片中维生素K2含量检测研究
多种维生素片中维生素K2含量检测研究杨菊辉（哈药集团制药六厂，黑龙江哈尔滨 150056）摘 要：目的：建立快速测定多种维生素片中维生素K2含量的分析方法。
方法：样品使用美国Waters公司高效液相色谱仪检测，C18色谱柱（250 mm×4.6 mm，5 μm）分离，流动相为甲醇，流速为1.0 mL·min-1。
结果：维生素K2保留时间约为54 min，在1.25～10.00 μg·mL-1线性关系良好，相关系数为0.998 2。
重复性实验相对标准偏差为1.69%，50%加标回收率为92.21%～100.22%，检出限为0.06 μg·g-1，定量限为0.20 μg·g-1。
结论：该方法准确度和精密度良好，灵敏度高，分离度好，可为多种维生素片中维生素K2的检测研究提供参考。
关键词：高效液相色谱检测法；维生素K2；保健食品Study on Vitamin K2 Content Detection in MultivitaminTabletsYANG Juhui(Harbin Pharmaceutical Group No.6 Pharmaceutical Factory, Harbin 150056, China) Abstract: Objective: To establish an analytical method for the rapid determination of vitamin K2 content in multivitamin tablets. Method: Samples were detected using a US Waters HPLC chromatograph, separated with a C18 column (250 mm×4.6 mm, 5 μm), mobile phase in methanol at a flow rate of 1.0 mL·min-1. Result: Vitamin K2 retention time was about 54 min, with a good linear relationship in the concentration 1.25～10.00 μg·mL-1 range, the correlation coefficient was 0.998 2. The relative standard deviation of the repeatability experiments was 1.69%, and the 50% spiking recovery was 92.21%～100.22%. The limit of detection was 0.06 μg·g-1 and the limit of quantification was 0.20 μg·g-1. Conclusion: This method has good accuracy and precision, high sensitivity and good separation degree, which can provide a reference for the detection of vitamin K2 in various vitamin tablets.Keywords: HPLC detection method; vitamin K2; health food维生素K是一类具有叶绿醌生物活性的萘醌基团的衍生物。
【VIP专享】Bi-weekly report
#9(270) 11(366) #12(252) #13(209)Fig1.1 EL images of SEII0042#9 #11 #12 #13Fig1.2 IR images of SEII004210090group A #3 (335) group B #15(409)Fig2.1 EL images of SEII0043型工艺制作电池片，A组在磷扩散的程序中加了700℃吸杂1h的过程，B组则是普通的高低温扩散程序。
由于在烧结温度没有调节好，所以吸杂组的FF普遍较差，从而导致EFF也较低，但即使是在没有烧结好的情况下，吸杂组的电流仍比未吸杂组的电流高，由此可以看出，吸杂对电池片性能有比较正面的影响，但结果还有待更多试验的进一步证实。
同时，本批电池片在实验室制绒，从Fig2.3可以看出，实验室制绒的效果不如车间，尤其是在长波部分有较大的差距。
Fig2.2的QE测试结果显示，反射率在短波部分的损失较大，对QE响应有一定的影响。
4.Discussions1)We will try 48fingers& 51fingers.2)P diffusion with 700℃ gettering process can bring advantageous effect, especially in Isc, we will repeatthis experiment to get clear conclusion.3)We have get good proportion of purple etching solution in 1L, in the future we will adjust proportion in7L.。
富士通 生活本U9312数据表说明书
Data Sheet Fujitsu Notebook LIFEBOOK U9312Fujitsu recommends Windows 11Pro.Data SheetFujitsu Notebook LIFEBOOK U9312Are you looking foraslim,breathtakingnotebookforfrequent business trips?Availablein redand black,the ultra-mobile Fujitsu LIFEBOOK U9312weighs only 885g.Enterprise-grade securityfeatures such asPalmSecure ™keepyour business dataprotected fromunauthorized access.Powerful performance andthe embedded 5Gor L T Eofferyou thebest-in-classuserexperience.Ultra-Slim and lightweight designExtraordinarily lightweight design forbusiness professionals who arealways on the move ■A remarkablyslim15.5mmnotebookweighing only 885 g with aminimalist style in a magnesium housing■Appealing ultra-slim notebook with backlit keyboard available in red or black color ■The best viewing experience is guaranteed by an anti-glare 13.3-inch FHD (1920 x 1080) display, with optional touch or non-touch screen■Durability is Military Standard MIL-STD-810H tested ■Maximum security■Protect your notebook and business data from unauthorized access at all times ■Integrated PalmSecure ™or fingerprint sensor■HD Infrared Camera allows face recognition with Windows Hello■Ultra-tiny Privacy Camera Shutter ■Kensington Lock support■SmartCard reader and TPM 2.0■Convenient mobility on the go. Highest productivity on business trips.■All-day battery runtime offers you the exceptional mobility that you need when on the move■Anytime USB Charge functionality to charge telephones and other media devices, even when the system is turnedoff■Powerful performance,thanks to integrated SSDs,helping to process data faster Your Light and ElegantTravelCompanionExcellent connectivityBeflexibleandstay productive in ahyper-connectedworld■Compactand versatileI n t e l ®Thunderbolt ™4connectorto charge your laptop,transferfilesat fast speeds,connect externalmonitors andotherperipherals■Full set of interfaceswith afull-sized HDMI,full-sized Flap-style LAN connector ■WLAN,Bluetoothand5Gor L TEComponentsBaseunit LIFEBOOK U9312black LIFEBOOK U9312redOperating systemsOperating system pre-installed Windows11 P r o.FujitsurecommendsWindows11Proforbusiness. Windows 11 HomeWindows10 P r o.FujitsurecommendsWindows11Proforbusiness.Microsoft OS support information Aftertheendoftheproduct lifeFujitsuwill continue totestand support allupcoming Windows releases foraperiod ofmaximum5years,depending on theavailable extensionof hardwareservicesthrough FujitsuWarranty topups.Fordetailspleasesee“Fujitsu Service StatementforWindows General Availability Channel”athttps:///IndexProdSupport.asp?lng=com&OpenTab=Operating system notes TheuseofWindows Operating Systemissubjectto acceptanceof theEndUserLicense Agreement ofMicrosoft as applicable under the relevant Microsoft program.Processor I n t e l®Core™i7-1265Uprocessor(10Cores,up to4.8GHz)I n t e l®Core™i5-1245Uprocessor(10Cores,upto4.4GHz)I n t e l®Core™i5-1235Uprocessor (10Cores,up to4.4GHz)**Processor only forr etai l,SMB,educationandgovernmentHarddiskdrives(internal)PCIe-SSD,512 GBM.2NVMe module,SEDPCIe-SSD,256 GBM.2NVMe module,SEDPCIe-SSD,2T BM.2NVMemodule,SEDPCIe-SSD,1T BM.2NVMe module,SEDHard disknotes Accessiblecapacity mayv ar y,also depending on usedsoftware.One Gigabyte equals one billion bytes,when referringtoharddiskdrivecapacity.Upto 20GBof HDDspace isreserved forsystemrecoveryDurability in accordancewith the manufacturer’s indications on readandwrite cycles. Interfaceaddoncards/components(optional)4G/5G(optional)FibocomFM350-GL(5GSub-6/Cat.19)(Downlink speed 5G-3740 MB/s,4G-1600 MB/s,Uplink speed5G-835 MB/s, 4G -211MB/s)Display33.8cm(13.3-inch),LEDbacklight,FHD,1,920x1,080pixel,Anti-glare IPS display,400c d/m²,1000:133.8cm(13.3-inch),IPS,FHD,1,920x1,080pixel,Anti-glare multi-touch,350c d/m²,1500:1MultimediaCamera Optional:Built-in HD webcamBase unitBaseunit LIFEBOOK U9312black LIFEBOOK U9312redGeneral system informationChipset Integrated in CPUGeneral system informationSupportedcapacity RAM(min.)8GBSupportedcapacity RAM(max.)32GBMemorynotes8GB/16GB/32GB onboardLPDDR4x (4,266MHz)DualchannelsupportLAN10/100/1,000MBit/s I n t e l®I219LMIntegrated WLAN IntelWi-F i6EAX211-WLAN,B T,SRD cat.2BIOS version UEFI Specification2.8BIOS features InsydeH2OBIOSAudio type OnboardAudio codec RealtekALC257Audio features2xbuilt-in speakers(stereo)MIL-STD tested Y e s,selectedMIL-STD-810H tests passed.MIL-STD-810H testresults arenot aguaranteeof futureperformance under identified testconditions. Accidental damage is not coveredunder standardinternational limited warranty.Color Black RedMaterial Magnesium MagnesiumDisplayDiagonal Size33.8cm(13.3-inch)Resolution(native)1,920 x1,080pixelGraphicsBaseunit LIFEBOOKU9312black LIFEBOOK U9312redGraphicsbrand name I n t e l®I r i s®XeGraphics I n t e l®I r i s®XeGraphicsGraphicsnotes Sharedmemorydepending on mainmemorysize andoperating systemInterfacesAudio: line-out/headphone1(comboport with Audio line-in)1(comboport with Audio line-in)Internal microphones2xdigital arraymicrophones(optional)2xdigital arraymicrophones(optional)USB3.2Gen1(5Gbps)total2xType-A(1with Anytime USBchargefunctionality)2xType-A(1with Anytime USBchargefunctionality)USB4.0Gen3(20Gbps) total2xType-C I n t e l® Thunderbolt™4(40 Gbps),Power Delivery(15W),DPout 2xType-C I n t e l® Thunderbolt™4(40 Gbps), Power Delivery(15W),DPoutUSBType-C USB4Gen3Thunderbolt™4,Power Delivery(15W),DP1.4USB4Gen3Thunderbolt™4,Power Delivery(15W),DP 1.4HDMI1Supports4k@60Hzasspecifiedin HDMI2.01Supports4k@60Hzasspecifiedin HDMI2.0 Ethernet(RJ-45)11Memorycardslots1SD4.0 StandardSD/microSD cardSDHC/microSDHC cardSDXC/microSDXC cardSpeedClass:uptoUHS-II 1SD4.0 StandardSD/microSD card SDHC/microSDHC card SDXC/microSDXC card SpeedClass:uptoUHS-IISmartCard slot1(optional)1(optional)SIM cardslot1(Nano-SIM,only formodelswith integrated5G/4G module)1(Nano-SIM,only formodelswith integrated 5G/4G module)eSIM card eSIM supported-integrated in4G/5GL T EModule eSIM supported-integrated in4G/5GL T EModule Docking connectorforPortReplicatorUSBType-C Portreplicator USBType-C PortreplicatorKensington Locksupport11Port Replicatorinterfaces(optional)USBType-C PR Thunderbolt™4PRDC-in1(19V/90Wrequired)1(20V/170W required)Poweron switch11Audio:comments1Combojackforheadsetusage1CombojackforheadsetusageDisplayPort1xV1.22xV1.4++VGA1---HDMI text1V2.0bPort Replicatorinterfaces(optional)Interface Notes3xType-A-5V/0.9A,4.5W1xType-C-15W1xType-C-Upto 60W(PD v2.0-1.1)poweroutputtoclientor 4.5Winput 2xType-A-5V/0.9A,4.5W1xType-A-5V/2.4A,12W2xType-C-5V,1.5A/4.5W charging port1xType-C-T B T4upto 60W(PDv2.0-1.1),5-20V/3.0A upstream(P C),Intel AMTsupport(vPRO)1xType-C-T B T4upto 15W(PDv2.0-1.1),5V/3.0A downstream,power outputtoclientKensington Locksupport no1Ethernet(RJ-45)11(10/100/1000Mbit/s,2,5Gbps)Notes Number of simultaneous useddisplays andits possibleresolutions andfrequencies dependon mobile systemand display interface type.Pleaseconsult alwaysalso themanualofthe connectedclient.Keyboardandpointing devicesBacklitkeyboardw/otouchstickNumber ofkeyboardkeys:85,Keyboardpitch:19 m m,Keyboardstroke:1.5mmMulti gesture touchpad with twomouse buttonsWireless technologiesAntennas 2 Dual bandWLAN antennas,2+2L T EantennasoptionalBluetooth v5.2Integrated WLAN IntelWi-F i6EAX211-WLAN,B T,SRD cat.2WLANencryption WP A/WP A2/WP A3(Wi-F i ProtectedAccess)WLANnotes WiFi6Eis supportedbyWindows11OS only-Windows10 OS supportsWiFi6only.#Import and usageaccording to country-specific regulations.Integrated WWAN(5G)L T EFibocomFM350-GL(Sub-6/Cat.19)-UMTS,LTE,5GWWANnotes OptionalGPS Embeddedin4G/5Gmoduleif configured withWWANPowersupplyACAdapter20V/65W(3.25A),100V-240V,50Hz -60H z,3-pin(grounded)Type-C AC-Adapter slim&light 20V/65W(3.25A),100V-240V,50Hz -60H z,3-pin (grounded)Type-C AC-Adapter slim&lightNotes65WAC adapterforusage with system/min.90WAC Adapter forusage with PortReplicator 65WAC adapterforusage with system/min.90W AC Adapter forusage with PortReplicatorRatedvoltage range100V -240V (AC Input)100V -240V (AC Input)Rated frequency range50Hz-60Hz50Hz-60Hz1stbattery Lithiumpolymerbattery4-cell,64Wh,4,196mAh Lithiumpolymerbattery4-cell,64Wh,4,196mAh Battery features FastCharge:Upto 80%in1h FastCharge:Upto 80%in1hRuntime1st battery TBC TBCNoise emissionNoise emission Pleaser efertotheEcoDeclarationDimensions/Weight/EnvironmentalDimensions(W xD xH)307x197x15.5mm12.09x7.76x0.61inchWeight starting at885gWeight(lbs)starting at1.95lbsWeight notes Weight mayvarydepending on actualconfigurationOperating ambient temperature5-35°C(41-95°F)Operating relative humidity20-80%ComplianceProduct LIFEBOOK U9312Europe CECBGlobal TCOCertified9.0Additional SoftwareAdditional software(preinstalled)Fujitsu Plugfree Network(network managementutility)Fujitsu Anytime USB Charge UtilityFujitsu Battery UtilityFujitsu FunctionManagerFujitsu DeskUpdate(driver andutility tool)Additional software(optional)Microsoft Office(need to buy license to activate the pre-installed MicrosoftOffice) Drivers &Utilities DVD(DUDVD)RecoveryDVD forWindows®Additional software(notes)Useof additional softwareis subjectto proactive acceptanceofthe respective EndUserLicenseAgreementas applicable forthe relevant softwarewhether preinstalled oroptional.This also appliesforanyavailable patches thereof.ManageabilityManageability technology I n t e l®vPro™technology/iAMT(dependingonprocessor) PXEBoot codeWake-on-LANManageability software DeskViewClientDeskViewInstant BIOS ManagementSupportedstandards WMI(Windows ManagementInstrumentation)PXE(Preboot ExecutionEnvironment)DMI(DesktopManagementInterface)SMBIOS(SystemManagementBIOS) CIM(CommonInformation Model)BootP(made4you)Manageability link /fts/manageabilityPhysical Security Kensington LocksupportSystemandBIOS Security Userand supervisor BIOSpassword EraseDiskOptional:Trusted Platform Module(TPM2.0)UserSecurity Accessprotectionvia external SmartCardreader(optional)Hard diskpasswordAuthConductor Client Basic(secureauthentication solution)Embedded P al m S ecur e®sensor(optional) Embedded fingerprintsensor(optional)Accessprotectionvia internal SmartCard reader (optional) Hard diskpassword AuthConductor Client Basic(secure authentication solution)Embedded P alm S ecur e®sensor (optional)Embedded fingerprintsensor(optional)SecurityNotes Thesecurity features included in theproduct alonecannot protectfromanyand allintrusion attemptsandcyberattacks.Foran adequate overalllevelof ITsecurity,further ITsecurity measures(e.g.supplementaryvirusscannersettings,firewall,access rights management,encryption etc.)must be adoptedindependentlyof theavailable systemconfiguration options. HencetheoverallITsecurity fortheproductis within the soleresponsibility of therespective user/administrator ofthe product.WarrantyWarranty period 3 years Next Business DayWarranty type Onsite Service within metro areasWarrantyT er m s&Conditions https:///au/support/client-computing-devices/notebooks/Digitalbug fixes Subject to availability and following their generic release forthe product,bug fixes and function-preservingpatches forproduct-related software(firmware)canbe downloaded fromthe technical support a t:https:///freeof chargeby entering therespective product serial number.Forapplicationsoftwaresuppliedtogether with the product,pleasedirectlyr efertothe support websites of therespectivesoftwaremanufacturer.ProductSupport Services-theperfectextensionRecommendedService9x5,Onsite ResponseT i m e:Next BusinessDaySparePartsavailability5yearsafterendofproduct lifeService Weblink /emeia/products/product-support-services/Thunderbolt ™4Port ReplicatorFirstThunderbolt ™Port Replicatoron the marketproviding enhanced security and fullsupport ofI n t e l ®AMT(vPro®).Theuniversalport caneasily connectalmosteverything with asingle cable andhigh speed-datatransfer.This smart workspace solution keepsyour deskcleanandtidy.USBType-C Port Replicator2Connecttoyour peripherals.Adapt tothetaskon demand.The universal USBType-C interface supports you toget your peripheral devices connectedeasily.MultiplyyourUSB portsto connectyour peripheralsas wellasyour externaldisplay via HDMI,DisplayPort or VGA.Youalso canchargeyour external USBdeviceswithouttheneedof any additional charger.RecommendedAccessoriesMore informationFujitsu products,solutions&servicesIn addition toFujitsuTabletLIFEBOOKU9312,Fujitsuprovides arange ofplatform solutions.They combine reliableFujitsu productswith thebest inservices,know-how,andworldwidepartnerships.Fujitsu PortfolioBuilding on industrystandards,Fujitsu offers afullportfolio of IThardwareand software products,services,solutions, andcloud offerings,ranging from clients to data centersolutions,and includes thebroad stackof Business Solutions,aswellasthefullstack of Cloud offering.This allowscustomerst o leverage alternative sourcing and delivery models t o increase th ei r business agility an d t o improve th ei r I T operation’s reliability.Computing Products/global/products/ computing/Softwarehttps:///au/support/client-com puting-devices/notebooks/More informationTo learnmoreabout FujitsuTabletLIFEBOOK U9312pleasecontact yourFujitsu sales representative or FujitsuBusiness partner,or visit ourwebsite.https:///au/products/computing/pc/notebooks/Fujitsu Green Policy Innovation is ourworldwideproject forreducingburdenson theenvironment.Using our global know-h ow,weaimtocontribute tothecreationofasustainable environment forfuturegenerations through IT.Pleasefind further informationatSustainable Manufacturing -FujitsuUvance: Fujitsu AustraliaCopyrightsAllrights reserved,includingintellectual propertyrights.Changestotechnical data reserved.Deliveryissubjectto availability. Designationsmaybe trademarksand/or copyrightsof the respective manufacturer,theuseofwhich by thirdparties fortheir ownpurposesmayinfringe therights ofsuch owner.Copyright 2022 Fujitsu LimitedPleasenotethatthedatasheet reflectsthe technical specification with themaximum selectionof components forthenamed system andnot thedetailedscope of delivery.Thescope ofdelivery isdefined by theselectionofcomponentsatthe timeof ordering.Technical datais subject tomodificationand delivery subject to availability.Anyliability thatthedataand illustrationsarecomplete, actual,or correct isexcluded.Designations maybe trademarksand/orcopyrights of the respective owner,theuseofwhichby third parties fortheir ownpurposesmayinfringe therightsof suchowner.T h e overall product h as b een designedand manufactured f o r general offi ce u s e,regular personal use,andordinaryindustrial use.Fujitsu green policy innovationDisclaimerCONTACT FujitsuProduct Team Fujitsu Product Portfolio Website:Allrights reserved,includingintellectualpropertyrights.Changesto technicaldatareserved.Deliveryis subjectto availability.Designations maybetrademarksand/orcopyrights of therespectivemanufacturer,theuseofwhich by thirdpartiesfortheir own purposes mayinfringetherights ofsuch owner.Copyright2022FujitsuProduct。
美国联合保健公司产品说明书：测试生成产品
UnitedHealthcare PharmacyClinical Pharmacy ProgramsProgram Number 2023 P 2018-16Program Prior Authorization/Medical Necessity – TestosteroneMedication Androderm, Androgel*, Fortesta*, Jatenzo*, Natesto*, Kyzatrex*,Testim, testosterone topical solution (generic Axiron)*, testosteronetransdermal gel (generic Testim)*, Tlando*, Vogelxo*, Xyosted*P&T Approval Date 2/2014, 4/2014, 5/2014, 7/2014, 10/2014, 10/2015, 5/2016, 6/2017,6/2018, 2/2019, 6/2019, 7/2020, 8/2021, 9/2022, 1/2023Effective Date 4/1/2023;Oxford only: 4/1/20231.Background:Testosterone products are approved by the Food and Drug Administration (FDA) for testosterone replacement therapy in males with primary hypogonadism (congenital or acquired) orhypogonadotropic hypogonadism (congenital or acquired). Primary hypogonadism originatesfrom a deficiency or disorder in the testicles. Secondary hypogonadism indicates a problem in the hypothalamus or the pituitary gland. Testosterone use has been strongly linked to improvements in muscle mass, bone density, and libido.The purpose of this program is to provide coverage for androgens and anabolic steroid therapy for the treatment of conditions for which they have shown to be effective and are within the scope of the plan’s pharmacy benefit. Coverage for the enhancement of athletic performance or bodybuilding will not be provided.a3.Additional Clinical Rules:•Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)and/or claim logic. Use of automated approval and re-approval processes varies by programand/or therapeutic class.•Supply limits may be in place.•* May be excluded from coverage•+ Coverage for patient population may be dependent upon benefit design4.References:1.AACE Hypogonadism Task Force. American Association of Clinical EndocrinologistsMedical Guidelines for Clinical Practice for the Evaluation and Treatment ofHypogonadism in Adult Male Patients – 2002 Update. Endocr Pract. 2002; 8(No. 6): 439-456.2.The World Professional Association for Transgender Health (WPATH), Standards of Carefor the Health of Transsexual, Transgender, and Gender Nonconforming People, 7thVersion.3.Cook, David M, et al. "American Association of Clinical Endocrinologists medicalguidelines for clinical practice for growth hormone use in growth hormone-deficient adultsand transition patients - 2009 update: executive summary of recommendations." Endocrinepractice 15.6 (2009):580-586.4.Gibney, James, et al. "Growth hormone and testosterone interact positively to enhanceprotein and energy metabolism in hypopituitary men." American journal of physiology:endocrinology and metabolism 289.2 (2005):E266-E2715.Bhasin, S, et al. "Testosterone replacement and resistance exercise in HIV-infected menwith weight loss and low testosterone levels." JAMA. 2000. 283.(6) 763-770.6.Isidori, Andrea M, et al. Effects of testosterone on sexual function in men: results of ameta-analysis. Clinical endocrinology. 2005 63(4):381-394.7.Kenny, A M, et al. Effects of transdermal testosterone on bone and muscle in older menwith low bioavailable testosterone levels. The journals of gerontology. 2001. 56(5) M266-M272.8.Tracz, Michal J, et al. Testosterone use in men and its effects on bone health. A systematicreview and meta-analysis of randomized placebo-controlled trials. The Journal of clinicalendocrinology and metabolism. 2006. 91(6):2011-2016.9.Bolona, Enrique R, et al. Testosterone use in men with sexual dysfunction: a systematicreview and meta-analysis of randomized placebo-controlled trials. Mayo Clinicproceedings.2007. 82(1):20-28.10.Androderm [package insert]. Madison, NJ: Allergan, Inc; May 2020.11.Androgel [package insert]. North Chicago, IL: AbbVie Inc; May 2020.12.Fortesta [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; January 2022.13.Testim [package insert]. Malvern, PA: Endo Pharmaceuticals Inc; August 2021.14.Natesto [package insert]. Mississauga, ON: Acerus Pharmaceuticals Corporation;December 2021.15.Vogelxo [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; April2020.16.Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab 2017; 102:3869.17.The Endocrine Society. Testosterone therapy in Adult Men with Androgen DeficiencySyndromes. J Clin Endocrinol Metab, May 2018, 103(5):1–30.18.Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline.American Urological Association Education and Research, Inc 2018.19.Xyosted [package insert]. Ewing, NJ: Antares Pharma, Inc; November 2019.20.Jatenzo [package insert]. Northbrook, IL: Clarus Therapeutics, Inc; March 2019.21.Tlando [package insert]. Ewing, NJ: Antares Pharma, Inc; March 2022.22.Kyzatrex [package insert]. Raleigh, NC: Marius Pharmaceuticals LLC; September 2022.Program Prior Authorization/Medical Necessity - TestosteroneChange ControlDate Change2/2014 Create Prior Authorization Criteria4/2014 Revised Reauthorization Criteria; formatting corrections, referencesupdated.5/2014 Revised the initial authorization criteria to include subsections for themale population and the female to male transsexual population, updatedto include language from the gender identity disorder/ gender dysphoriatreatment medical coverage determination guideline, referencesupdated7/2014 Added Natesto and Vogelxo to criteria. Changed coverage criteria fromspecific product names to topical testosterone products.10/2014 Modified criteria for total testosterone to consider reference range of thelaboratory. Added criteria for when Free Testosterone level may beutilized. Added criteria for conditions that do not require testosteronelevels. Extended initial authorization period for patients already ontherapy.12/2014 Testosterone free level units corrected.10/2015 Clarified initial authorization periods. Clarified that levels forreauthorization should be within the past 6 months for patients new totestosterone and within the past 12 months for continuing users.Updated references.5/2016 Removed age requirement from female to male transsexual coveragerequirements. Updated gender identity disorder to gender dysphoria.6/2017 Updated criteria for Gender Dysphoria. Updated reauthorizationcriteria to clarify that new to therapy refers to use of less than one yearand continuing therapy refers to use of one year or longer.6/2018 Updated required testosterone level to less than 300 ng/dL based on2018 American Urological Society treatment guidelines.2/2019 Program name change from Topical Androgens to Testosterone.Xyosted added to program.6/2019 Jatenzo added to program.7/2020 Updated initial authorization to 6 months for both new and existingusers. Added state mandate language. Updated references.8/2021 Annual review. Updated references. Removed Striant as it is no longeron the market.9/2022 Tlando added to program. Removed brand Axiron from program sinceit is no longer available. Updated to note generic Testim is typicallyexcluded. Updated references.1/2023 Kyzatrex added to program. Increased initial authorization to 12months and changed reauthorization to require a lab value within thepast 12 months.。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Date:Week Two
Class:Story
Teacher: Jamie
Subject of the book: It is spring
Teaching material:Flashcards, VCD, Book and wall chart
Objective:Introduce New vocabulary
Words:Dress, Sweet, Father, Mother, Brother, Sister
:
Steps:Use Flash cards for words and Pictures to help the children learn.
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week Three
Class:English First
Teபைடு நூலகம்cher: Jamie
Subject of the book: Easter
Teaching material:Flashcards, VCD, Book and wall chart
Objective:to review all words and letters learn
Steps:Use Flash cards for words and Pictures to help the children review
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week Two
Class:Hello Teddy
Teacher: Jamie
Subject of the book: Toys
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week Three
Class:Hello Teddy
Teacher: Jamie
Subject of the book: Body
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week one
Class:Story
Teacher: Jamie
Subject of the book: It Is spring
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week four
Class: Hello Teddy
Teacher: Jamie
Subject of the book: Revision
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week four
Class: Story
Teacher: Jamie
Subject of the book: Revision
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week Two
Class:English first
Teacher: Jamie
Subject of the book: It is spring
Teaching material:Flashcards, VCD, Book and wall chart
Objective:To learn the book and new vocabulary
Steps:Read the book with children asking them to repeat and encourage them to interact with the story.
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week one
Class:English First
Teacher: Jamie
Subject of the book: Spring
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week one
Class:Hello Teddy
Teacher: Jamie
Subject of the book: Greetings
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week four
Class: English First
Teacher: Jamie
Subject of the book: Revision
Teaching material:Flashcards, VCD, Book and wall chart
Objective:to review all words and letters learn
Steps:Use Flash cards for words and Pictures to help the children review
Teaching material:Flashcards, VCD, Book and wall chart
Objective:To understand and learn new vocabulary.
Words: Ant, Bee , Flower, Grass
:
Steps:Use Flash cards for words and Pictures to help the children learn
Teaching material:Flashcards, VCD, Book and wall chart
Objective:To understand and learn new words
Words : Basket , Egg, Rabbit
Steps:Use Flash cards for words and Pictures to help the children learn
Teaching material:Flashcards, VCD, Book and wall chart
Objective:to review all Books learnt
Steps:Use Teachers story books to review.
Teaching material:Flashcards, VCD, Book and wall chart
Objective:To understand and learn new vocabulary
Words : Ball, Kite, Cards, doll, Water pistol
Steps:Use wall chart and flash cards. Play a game with the flash cards to have fun and help them learn.
Teaching material:Flashcards, VCD, Book and wall chart
Objective:To learn and understand the book
Steps:Read the book with children asking them to repeat and encourage them to interact with the story
Teaching material:Flashcards, VCD, Book and wall chart
Objective:Introduce the children to two songs. I miss you my friend and Little Johnny.
:
:
Steps:Sing and use hello teddy DVD to learn new songs
Tianjian child-loving kindergarten (2011-2011) The Second term foreignteacher’s Lesson plan
Date:Week Three
Class:Story
Teacher: Jamie
Subject of the book:
Teaching material:Flashcards, VCD, Book and wall chart
Objective:To learn the book and new vocabulary